Windtree Therapeutics Files 8-K with Material Agreements
Ticker: WINTW · Form: 8-K · Filed: Jul 17, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
Related Tickers: WTW
TL;DR
WTW filed an 8-K detailing material agreements and equity sales - check for shareholder impact.
AI Summary
On July 16, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and material modifications to the rights of security holders. This filing also includes information regarding Regulation FD disclosure and financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by Windtree Therapeutics, including new agreements and potential changes for shareholders, requiring investor attention.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- July 16, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Windtree Therapeutics?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on July 16, 2025.
What type of equity securities were sold in the unregistered sales?
The filing mentions unregistered sales of equity securities but does not provide details on the specific type or amount of securities sold.
What modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders but does not elaborate on the specific changes.
Does this 8-K filing include financial statements?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information.
What is the company's primary business sector?
Windtree Therapeutics, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, SIC code 2836.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding WINDTREE THERAPEUTICS INC /DE/ (WINTW).